Comparison of whole blood transcriptional changes induced by menignoccocal capsular group B vaccines in mice
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus
PROVIDER: GSE139529 | GEO | 2020/10/16
REPOSITORIES: GEO
Similar Datasets
Project description:Whole blood RNA-seq was leveraged to explore gene expression changes induced in mice 24 hours after immunisation with a second dose of a licensed vaccine against capsular group B meningococcus, one of the vaccines components, or one of several comparator groups.
2019-05-30 | GSE131914 | GEO
Project description:Whole blood RNA-seq and single cell RNA-seq on neutrophils was leveraged to explore gene expression changes induced in mice 24 hours after immunisation with a second dose of a licensed vaccine against capsular group B, meningococcus, the same vaccine in combination with routinely-administered vaccines, routine vaccines on their own, or a PBS control immunisation.
2019-06-06 | GSE132199 | GEO
Project description:The oil-in-water emulsion Adjuvant System 03 (AS03) is one of the few adjuvants used in licensed vaccines. AS03 induces a local and transient inflammatory response that contribute to its adjuvant effect. This data provides a more comprehensive analysis of early gene expression both at the injection site and in the draining lymph node 2, 4 or 6 hours after immunisation with AS03.
2018-06-26 | E-MTAB-6632 | biostudies-arrayexpress
Project description:Comparison of whole blood transcriptional changes induced by menignoccocal capsular group B vaccines in mice
| PRJNA580190 | ENA
Project description:The primary mechanism by which pneumococcal capsular polysaccharide-based vaccines are believed to mediate protection is by induction of serotype-specific opsonic antibodies that facilitate bacterial killing by phagocytes (opsonophagocytosis). However, antibodies that are protective against experimental pneumococcal pneumonia in mice but do not promote opsonophagocytic killing in vitro have also been identified 1-3. Such non-opsonic antibodies are associated with bacterial clearance in vivo, but the mechanism by which this occurs is unknown. In this letter, we demonstrate that a protective, non-opsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody (MAb) enhances quorum sensing, which results in competence induction and fratricide of serotype 3 pneumococcus. Gene expression profile analysis revealed that the MAb together with the pneumococcal autoinducer, competence stimulating peptide 2 (CSP2), augments differential expression of competence (com) related bacteriocin-like peptide (blp) genes that are known to be involved in pneumococcal fratricide. Taken together, these findings reveal a previously unsuspected mechanism of antibody action, namely, enhancement of quorum sensing and bacterial fratricide. Given that this activity does not require phagocytes, antibodies that function accordingly may hold promise as adjuncts to current vaccines or as desired products of next generation pneumococcal vaccines. 6 samples
2011-03-01 | E-GEOD-27258 | biostudies-arrayexpress
Project description:The primary mechanism by which pneumococcal capsular polysaccharide-based vaccines are believed to mediate protection is by induction of serotype-specific opsonic antibodies that facilitate bacterial killing by phagocytes (opsonophagocytosis). However, antibodies that are protective against experimental pneumococcal pneumonia in mice but do not promote opsonophagocytic killing in vitro have also been identified 1-3. Such non-opsonic antibodies are associated with bacterial clearance in vivo, but the mechanism by which this occurs is unknown. In this letter, we demonstrate that a protective, non-opsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody (MAb) enhances quorum sensing, which results in competence induction and fratricide of serotype 3 pneumococcus. Gene expression profile analysis revealed that the MAb together with the pneumococcal autoinducer, competence stimulating peptide 2 (CSP2), augments differential expression of competence (com) related bacteriocin-like peptide (blp) genes that are known to be involved in pneumococcal fratricide. Taken together, these findings reveal a previously unsuspected mechanism of antibody action, namely, enhancement of quorum sensing and bacterial fratricide. Given that this activity does not require phagocytes, antibodies that function accordingly may hold promise as adjuncts to current vaccines or as desired products of next generation pneumococcal vaccines.
2011-03-01 | GSE27258 | GEO
Project description:The time course of whole blood gene expression was determined in healthy adult participants residing in an inpatient unit (CRC, University of Surrey, UK) to minimise background environmental variation, who were randomised into three protocols (305A, 305B and 305C) with study groups within each protocol (n = 20/21) receiving a single immunisation with a licensed vaccine or saline placebo control.
2019-01-06 | GSE124533 | GEO
Project description:Diagnostic primer extension assay to serotype Streptococcus pneumoniae. Assay validation. Background: Monitoring of Streptococcus pneumoniae serotype epidemiology is essential since serotype replacement is a concern when introducing new polysaccharide-conjugate vaccines. To simplify S. pneumoniae serotyping, a novel PCR-based automated microarray assay was developed to assist in the tracking of the serotypes. Results: Autolysin (lytA), pneumolysin (ply) and eight genes located in the capsular operon (cps) were amplified using multiplex PCR. This step was followed by a tagged fluorescent primer extension step targeting serotype-specific polymorphisms. The tagged primers were then hybridized to a microarray. Results were exported to an expert system that transforms genetic typing data into capsular serotype identification. The assay was validated on 166 cultured S. pneumoniae samples from 63 different serotypes as determined by the Quellung method. In addition, the assay was tested on clinical specimens including 43 cerebrospinal fluid samples from patients with meningitidis and 59 nasopharyngeal aspirates from bacterial pneumonia patients. The assay presented with no cross-reactivity for 24 relevant bacterial species found in these types of samples. The limit of detection for serotyping and S. pneumoniae detection was 100 genome equivalent per reaction. Conclusion: This automated assay is amenable to clinical testing and does not require any culturing of the samples. The assay will be useful for the evaluation of serotype prevalence changes after new conjugate vaccines introduction. 166 quellung serotyped strains and two negative controls
2013-12-31 | E-GEOD-45865 | biostudies-arrayexpress
Project description:To use proteomic analysis to qualitatively and quantitatively identify mammalian protein components of commercial veterinary vaccines against canine distemper, leptospirosis, borreliosis, and rabies. A total of 25 licensed veterinary vaccines (from 4 different manufacturers) against canine distemper and leptospirosis, borreliosis, and rabies (3 year and 1 year duration of immunity) were analyzed. Duplicate samples from a single lot vial of each vaccine were prepared by acetone precipitation and proteolysis with trypsin and lysC protease mix. Peptides mixtures (one microgram) were analyzed by LC-MS using Orbitrap Fusion Lumos mass spectrometer. LC-MS data were searched against a Bos taurus protein database using MaxQuant to identify and quantify mammalian proteins in the vaccines. Protein classification and network analysis was performed of iIdentified proteins were classified by function and network analysis to visualize interactions. The largest number of mammalian proteins was identified in 3-year rabies vaccines (median 243, range 184-339) and 1 year rabies vaccines (median 193, range 169-350). Borrelia and leptospirosis-distemper (L and D) vaccines had the lowest number of proteins. Rabies vaccines had the largest number of identified proteins in common (316), 33 were unique to 1 year and 44 in 3 year products. Borrelia and L and D vaccines had 16 and 22 uniquely identified proteins, respectively. The protein classifications were primarily as modulators of protein-binding activity, enzymes, transfer/carrier proteins, cytoskeletal proteins, defense or immunity proteins, calcium-binding proteins, and extracellular matrix proteins.
2022-12-06 | MSV000090844 | MassIVE
Project description:Diagnostic primer extension assay to serotype Streptococcus pneumoniae. Assay validation. Background: Monitoring of Streptococcus pneumoniae serotype epidemiology is essential since serotype replacement is a concern when introducing new polysaccharide-conjugate vaccines. To simplify S. pneumoniae serotyping, a novel PCR-based automated microarray assay was developed to assist in the tracking of the serotypes. Results: Autolysin (lytA), pneumolysin (ply) and eight genes located in the capsular operon (cps) were amplified using multiplex PCR. This step was followed by a tagged fluorescent primer extension step targeting serotype-specific polymorphisms. The tagged primers were then hybridized to a microarray. Results were exported to an expert system that transforms genetic typing data into capsular serotype identification. The assay was validated on 166 cultured S. pneumoniae samples from 63 different serotypes as determined by the Quellung method. In addition, the assay was tested on clinical specimens including 43 cerebrospinal fluid samples from patients with meningitidis and 59 nasopharyngeal aspirates from bacterial pneumonia patients. The assay presented with no cross-reactivity for 24 relevant bacterial species found in these types of samples. The limit of detection for serotyping and S. pneumoniae detection was 100 genome equivalent per reaction. Conclusion: This automated assay is amenable to clinical testing and does not require any culturing of the samples. The assay will be useful for the evaluation of serotype prevalence changes after new conjugate vaccines introduction.
2013-12-31 | GSE45865 | GEO